Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.13, RTT News reports. During the same period last year, the firm posted ($0.21) EPS.
Larimar Therapeutics Trading Down 2.8 %
NASDAQ:LRMR traded down $0.24 on Thursday, reaching $8.23. The stock had a trading volume of 533,870 shares, compared to its average volume of 567,334. The company has a 50-day moving average of $7.33 and a 200 day moving average of $7.80. The stock has a market cap of $524.81 million, a P/E ratio of -7.55 and a beta of 0.98. Larimar Therapeutics has a 12-month low of $2.18 and a 12-month high of $13.68.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Larimar Therapeutics in a research report on Thursday. Wedbush assumed coverage on Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $22.00 price objective on the stock. Baird R W upgraded Larimar Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 4th. Robert W. Baird initiated coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an "outperform" rating and a $16.00 target price on the stock. Finally, Oppenheimer assumed coverage on Larimar Therapeutics in a research report on Wednesday, October 16th. They set an "outperform" rating and a $26.00 target price on the stock. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $20.43.
Read Our Latest Stock Report on Larimar Therapeutics
Larimar Therapeutics Company Profile
(
Get Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Recommended Stories
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
